KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AbbVie (ABBV) Free Cash Flow (2016 - 2025)

Historic Free Cash Flow for AbbVie (ABBV) over the last 14 years, with Q3 2025 value amounting to $6.6 billion.

  • AbbVie's Free Cash Flow rose 2779.92% to $6.6 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $19.7 billion, marking a year-over-year increase of 2599.37%. This contributed to the annual value of $17.8 billion for FY2024, which is 1917.32% down from last year.
  • Latest data reveals that AbbVie reported Free Cash Flow of $6.6 billion as of Q3 2025, which was up 2779.92% from $4.9 billion recorded in Q2 2025.
  • In the past 5 years, AbbVie's Free Cash Flow ranged from a high of $7.7 billion in Q3 2021 and a low of $1.4 billion during Q1 2025
  • For the 5-year period, AbbVie's Free Cash Flow averaged around $5.2 billion, with its median value being $4.9 billion (2025).
  • In the last 5 years, AbbVie's Free Cash Flow crashed by 6694.35% in 2024 and then surged by 14059.11% in 2025.
  • AbbVie's Free Cash Flow (Quarter) stood at $4.9 billion in 2021, then soared by 47.61% to $7.2 billion in 2022, then plummeted by 36.96% to $4.5 billion in 2023, then soared by 48.57% to $6.8 billion in 2024, then dropped by 1.69% to $6.6 billion in 2025.
  • Its Free Cash Flow stands at $6.6 billion for Q3 2025, versus $4.9 billion for Q2 2025 and $1.4 billion for Q1 2025.